The estimated Net Worth of Nina S Kjellson is at least $345 millier dollars as of 20 April 2015. Nina Kjellson owns over 200,000 units of Eiger BioPharmaceuticals Inc stock worth over $345,000 and over the last 10 years Nina sold EIGR stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Nina Kjellson EIGR stock SEC Form 4 insiders trading
Nina has made over 1 trades of the Eiger BioPharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Nina bought 200,000 units of EIGR stock worth $3,200,000 on 20 April 2015.
The largest trade Nina's ever made was buying 200,000 units of Eiger BioPharmaceuticals Inc stock on 20 April 2015 worth over $3,200,000. On average, Nina trades about 28,571 units every 0 days since 2015. As of 20 April 2015 Nina still owns at least 200,000 units of Eiger BioPharmaceuticals Inc stock.
You can see the complete history of Nina Kjellson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Nina Kjellson's mailing address?
Nina's mailing address filed with the SEC is 525 University Ave #610, Palo Alto, CA 94301, USA.
Insiders trading at Eiger BioPharmaceuticals Inc
Over the last 9 years, insiders at Eiger BioPharmaceuticals Inc have traded over $3,017,304 worth of Eiger BioPharmaceuticals Inc stock and bought 780,533 units worth $4,706,203 . The most active insiders traders include Richard A Kayne, Edgar Engleman et Partners X Lp Inter West Ma.... On average, Eiger BioPharmaceuticals Inc executives and independent directors trade stock every 70 days with the average trade being worth of $47,232. The most recent stock trade was executed by Richard A Kayne on 31 October 2023, trading 278,239 units of EIGR stock currently worth $72,342.
What does Eiger BioPharmaceuticals Inc do?
eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.
What does Eiger BioPharmaceuticals Inc's logo look like?
Complete history of Nina Kjellson stock trades at Cidara Therapeutics Inc et Eiger BioPharmaceuticals Inc
Eiger BioPharmaceuticals Inc executives and stock owners
Eiger BioPharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
David Cory,
President, Chief Executive Officer, Director -
David Apelian,
Director -
Stephana Patton,
Chief Compliance Officer, General Counsel, Corporate Secretary -
Sriram Ryali,
Chief Financial Officer -
David A. Cory M.B.A., R.Ph., R.Ph, MBA,
Bus. Founder, Pres, CEO & Director -
James Shaffer,
Chief Business Officer -
David A. Cory R.Ph, MBA,
Bus. Founder, Pres, CEO & Director -
Eldon C. Mayer III, M.B.A.,
Exec. VP & Chief Commercial Officer -
Sriram Ryali M.B.A.,
Chief Financial Officer -
Christine Murray,
Independent Director -
Thomas Dietz,
Independent Chairman of the Board -
Amit Sachdev,
Independent Director -
Evan Loh,
Independent Director -
Eldon Mayer,
Executive Vice President, Chief Commercial Officer -
Jeffrey Glenn,
Independent Director -
Dr. Evan Loh,
CEO of Paratek Pharmaceuticals & Director -
Dr. Jeffrey S. Glenn,
Founder, Scientific Advisor & Independent Director -
Dr. Stephana E. Patton J.D., Ph.D.,
Consultant -
Erik Atkisson,
Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Dr. Colin Hislop,
Sr. VP of Clinical & Devel. Operations -
Rich Franco M.B.A.,
Sr. VP & Progeria Program Lead -
Dr. Ingrid C. Choong,
Sr. VP of Clinical Devel. -
Charles Bramlage,
Director -
Edgar Engleman,
Director -
Joanne Quan,
Chief Medical Officer -
Eduardo Bruno Martins,
SVP, Liver and Infectious Dise -
Ventures Vi, Llc Vivo Ventu...,
-
James H Welch,
Chief Financial Officer -
Nina S Kjellson,
Director -
Kim Sablich,
-
Partners X Lp Inter West Ma...,
-
Ingrid Choong,
Chief Business Officer -
Erik Atkisson,
GC & Chief Compliance Officer -
Lisa Kelly Croswell,
-
James Vollins,
General Counsel -
Leen Kawas,
-
Richard A Kayne,